Evidence map›Paper›PMID 42209820›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Hugo Levillain, Anne Royer Moës, Cristiana Gameiro-Paris, Antero Abrunhosa, Tom Deakin, Geraldine Gebhart, Matthias M Herth, Jean-François Gestin, Ferid Haddad, Andreas Ingemann Jensen and 7 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hugo LevillainInstitut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium. hugo.levillain@hubruxelles.be.ORCID 0000-0003-3909-625X
Anne Royer MoësIBA SA, RadioPharmaSolutions, Brussels, Belgium.
Cristiana Gameiro-ParisIBA SA, RadioPharmaSolutions, Brussels, Belgium.
Antero AbrunhosaInstitute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal.ORCID 0000-0002-4145-854X
Tom DeakinLabLogic Systems Limited, Sheffield, UK.
Geraldine GebhartInstitut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.ORCID 0000-0001-8853-0783
Matthias M HerthTetraKit Technologies ApS, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-7788-513X
Jean-François GestinNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes, France.ORCID 0000-0002-2804-473X
Ferid HaddadGIP Arronax, Saint-Herblain, and Subatech, Nantes, France.ORCID 0000-0001-6971-5969
Andreas Ingemann JensenTetraKit Technologies ApS, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-4302-2982
Rebecca Lo BueThe Oncidium Foundation, Brussels, Belgium.
Renata MikolajczakRadioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland.ORCID 0000-0002-6882-751X
Adrian OtamendiVicomtech, San Sebastian, Spain.ORCID 0000-0001-5954-0915
Katie Staunton-MannLabLogic Systems Limited, Sheffield, UK.
Kevin TaburyBelgian Nuclear Research Centre (SCK CEN), Mol, Belgium.ORCID 0000-0002-8004-3718
Patrick FlamenInstitut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium.ORCID 0000-0003-2193-6599
Accelerate.EU consortium

Funding

Innovative Health Initiative 101173001
6 · The paper itself

Abstract

Targeted Alpha Therapy (TAT) holds considerable promise for precision oncology, yet its clinical deployment in Europe remains limited. Beyond scientific considerations, progress is constrained by fragmentation across the radiopharmaceutical value chain, encompassing radionuclide production, radiochemistry, preclinical validation, clinical development, regulatory frameworks, infrastructure, and workforce training. This editorial focuses on astatine‑211 (

Indexed as

Alpha ParticlesAstatineEuropeHumansRadiopharmaceuticalsAstatineAstatine-211RadiopharmaceuticalsACCELERATEAstatine-211Clinical trialsRadiopharmacySelf-imagingTargeted alpha therapyTheranostics

Identifiers

PMID42209820
PMCPMC13421222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.